Tumor Biology

, Volume 36, Issue 5, pp 3583–3589 | Cite as

RETRACTED ARTICLE: CIP2A mediates prostate cancer progression via the c-MYC signaling pathway

Research Article


Recent evidence suggests that cancerous inhibitor of protein phosphatase 2A (CIP2A) is an oncoprotein that acts as a novel therapeutic target in a variety of tumors. In this study, we investigated the clinical significance of CIP2A and its function in our large collection of prostate samples. Between August 2000 and December 2013, 126 patients with histologically confirmed PCa and 92 with benign prostate hyperplasia (BPH) were recruited into the study. Quantitative RT-PCR, Western blot, and immunohistochemistry analyses were used to quantify CIP2A expression in PCa clinical samples and cell lines. The relationships between CIP2A expression and clinicopathological features were analyzed. The functional role of CIP2A in PCa cells was evaluated by small interfering RNA-mediated depletion of the protein followed by analyses of cell proliferation and invasion. High expression of CIP2A staining was 86.51 % (109/126) in 126 cases of PCa and 17.39 % (16/92) in 92 cases of BPH, and the difference of CIP2A expression between PCa and BPH was statistically significant. CIP2A was significantly elevated in all five PCa cell lines when compared to the RWPE-1 cells at both the messenger RNA (mRNA) and protein levels. Silencing of CIP2A inhibited the proliferation of DU-145 cells which have a relatively high level of CIP2A in a time- and concentration-dependent manner, and the invasion and migration of DU-145 cells were distinctly suppressed. Furthermore, CIP2A knockdown led to substantial reductions in c-Myc levels in PCa cell lines, but no significant change in phosphorylated Akt expression after CIP2A knockdown in DU-145 cells. Our data suggest that the pathogenesis of human PCa maybe mediated by CIP2A, and CIP2A inhibition treatment may provide a promising strategy for the antitumor therapy of PCa, and thus CIP2A could represent selective targets for the molecularly targeted treatments of PCa.


Prostate cancer Cancerous inhibitor of protein phosphatase 2A Small interfering RNA Proliferation Invasion Targeted therapy 



This study was supported by the grants from the Science and Technology Research Projects of Guangzhou (No. 11A72070508, 2011Y-00003)

Conflicts of interest



  1. 1.
    Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010;46:765–81.CrossRefPubMedGoogle Scholar
  2. 2.
    Ren SC, Chen R, Sun YH. Prostate cancer research in China. Asian J Androl. 2013;15:350–3.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localized disease. Eur Urol. 2011;59(1):61–71.CrossRefPubMedGoogle Scholar
  4. 4.
    Saad F, Pantel K. The current role of circulating tumor cells in the diagnosis and management of bone metastases in advanced prostate cancer. Future Oncol. 2012;8(3):321–31.CrossRefPubMedGoogle Scholar
  5. 5.
    Lassi K, Dawson NA. Emerging therapies in castrate-resistant prostate cancer. Curr Opin Oncol. 2009;21:260–5.CrossRefPubMedGoogle Scholar
  6. 6.
    Li W, Ge Z, Liu C, Liu Z, Bjorkholm M, Jia J, et al. CIP2A is overexpressed in gastric cancer and its depletion leads to impaired clonogenicity, senescence, or differentiation of tumor cells. Clin Cancer Res. 2008;14:3722–8.CrossRefPubMedGoogle Scholar
  7. 7.
    Junttila MR, Puustinen P, Niemela M, Ahola R, Arnold H, Bottzauw T, et al. CIP2A inhibits PP2A in human malignancies. Cell. 2007;130:51–62.CrossRefPubMedGoogle Scholar
  8. 8.
    Khanna A, Bockelman C, Hemmes A, Junttila MR, Wiksten JP, Lundin M, et al. MYC-dependent regulation and prognostic role of CIP2A in gastric cancer. J Natl Cancer Inst. 2009;101:793–805.CrossRefPubMedGoogle Scholar
  9. 9.
    Come C, Laine A, Chanrion M, Edgren H, Mattila E, Liu X, et al. CIP2A is associated with human breast cancer aggressivity. Clin Cancer Res. 2009;15:5092–100.CrossRefPubMedGoogle Scholar
  10. 10.
    Qu YY, Dai B, Kong YY, Ye DW, Yao XD, et al. Prognostic factors in Chinese patients with metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy. Asian J Androl. 2013;15(1):110–5.CrossRefPubMedGoogle Scholar
  11. 11.
    Petrylak DP, Tangen CM, Hussain MH, Lara Jr PN, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351(15):1513–20.CrossRefPubMedGoogle Scholar
  12. 12.
    Wiegering A, Pfann C, Uthe FW, Otto C, Rycak L, Mäder U, et al. CIP2A influences survival in colon cancer and is critical for maintaining Myc expression. PLoS One. 2013;8(10):e75292.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Hemmes A, Leminen A, Westermarck J, Haglund C, Butzow R, et al. Prognostic role of CIP2A expression in serous ovarian cancer. Br J Cancer. 2011;105(7):989–95.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Ren J, Li W, Yan L, Jiao W, Tian S, et al. Expression of CIP2A in renal cell carcinomas correlates with tumour invasion, metastasis and patients survival. Br J Cancer. 2011;105(12):1905–11.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Junttila MR, Puustinen P, Niemela M, Ahola R, Arnold H, et al. CIP2 inhibits PP2A in human malignancies. Cell. 2007;130:51–62.CrossRefPubMedGoogle Scholar
  16. 16.
    Yeh E, Cunningham M, Arnold H, Chasse D, Monteith T, et al. A signaling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nat Cell Biol. 2004;6:308–18.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  1. 1.Department of UrologyFirst Affiliated Hospital of Jinan UniversityGuangzhouChina

Personalised recommendations